In Vitro Anti- Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657
- 1 May 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (5), 1072-1076
- https://doi.org/10.1128/aac.43.5.1072
Abstract
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori . Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 μg/ml, respectively) than those of amoxicillin and rifampin for H. pylori . Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.Keywords
This publication has 25 references indexed in Scilit:
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- Antimicrobial resistance and Helicobacter pyloriJournal of Antimicrobial Chemotherapy, 1996
- The susceptibility of Helicobacter pylori to the rifamycin, rifaximinJournal of Antimicrobial Chemotherapy, 1995
- The coccoid forms ofHelicobacter pylori. Criteria for their viabilityEpidemiology and Infection, 1993
- Synthesis and Biological Activity of 3'-Hydroxy-5'-aminobenzoxazinorifamycin Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1993
- Helicobacter pylori: Its Role in DiseaseClinical Infectious Diseases, 1992
- Helicobacter pyloriInfection and the Risk of Gastric CarcinomaNew England Journal of Medicine, 1991
- Cure of duodenal ulcer associated with eradication of Helicobacter pyloriThe Lancet, 1990
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988
- Mapping and sequencing of mutations in the Escherichia colirpoB gene that lead to rifampicin resistanceJournal of Molecular Biology, 1988